Article citationsMore>>

B. A. Griffin, D. J. Freeman, G. W. Tait, J. Thomson, M. J. Caslake, C. J. Packard and J. Shepherd, “Role of Plasma Triglyceride in the Regulation of Plasma Low Density Lipoprotein (LDL) Subfractions: Relative Contribution of Small Dense LDL to Coronary Heart Disease Risk,” Atherosclerosis, Vol. 106, No. 2, 1994, pp. 241- 253. doi:10.1016/0021-9150(94)90129-5

has been cited by the following article:

• TITLE: Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients

  AUTHORS: Gen Yoshino, Saburo Nakano, Tomoko Matsumoto, Eiichi Murakami, Toshisuke Morita, Koji Kuboki

  KEYWORDS: Rosuvastatin; Small Dense LDL-Cholesterol (sdLDL); Large Buoyant LDL-C (lbLDL-C); Apolipoprotein (apo) B; Small Dense LDL-Cholesterol (sdLDL)/Large Buoyant LDL-C (lbLDL-C) Ratio

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.1, January 12, 2012

  ABSTRACT: Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p